Second primary tumors in retinoblastoma

J. William Harbour, Amir Mohsenin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Advances in the diagnosis and treatment of retinoblastoma have vastly improved patient outcomes. In developed countries, the most common cause of death in patients with heritable retinoblastoma is now a second primary tumor occurring in retinoblastoma survivors; many of these second primaries can be avoided by the reduced use of radiation. Mesenchymal tumors including primitive neuroectodermal tumors, bone and soft tissue sarcomas, leiomyomas, lipomas, cutaneous melanomas, and gliomas are the most common types of the second primary tumors in retinoblastoma survivors. Osteogenic sarcoma is the most common type of second primary tumor particularly in younger patients. Widespread use of systemic chemotherapy only started in the mid-1990s, so it is still too early to know its long-term risk of second primary tumors. Ophthalmic arterial chemotherapy has been widely used for only a few years and, while a major goal of this therapy is to reduce systemic exposure to chemotherapy, a significant amount of radiation exposure to the orbit is required for the fluoroscopy needed to cannulate the ophthalmic artery. Thus, it will be many years before we know the long-term risk of ocular tumors associated with ophthalmic arterial chemotherapy. Regardless of the therapy used to treat intraocular retinoblastoma, it is important to provide lifelong surveillance for second primary tumors that may arise in the orbit and elsewhere in patients with germline retinoblastoma.

Original languageEnglish (US)
Title of host publicationOrbital Tumors: Diagnosis and Treatment, Second Edition
PublisherSpringer New York
Pages37-41
Number of pages5
ISBN (Print)9781493915101, 9781493915095
DOIs
StatePublished - Jan 1 2015

Fingerprint

Retinoblastoma
Neoplasms
Drug Therapy
Orbit
Survivors
Ophthalmic Artery
Primitive Neuroectodermal Tumors
Lipoma
Fluoroscopy
Leiomyoma
Osteosarcoma
Developed Countries
Glioma
Sarcoma
Cause of Death
Melanoma
Therapeutics
Radiation
Bone and Bones
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

William Harbour, J., & Mohsenin, A. (2015). Second primary tumors in retinoblastoma. In Orbital Tumors: Diagnosis and Treatment, Second Edition (pp. 37-41). Springer New York. https://doi.org/10.1007/978-1-4939-1510-1_5

Second primary tumors in retinoblastoma. / William Harbour, J.; Mohsenin, Amir.

Orbital Tumors: Diagnosis and Treatment, Second Edition. Springer New York, 2015. p. 37-41.

Research output: Chapter in Book/Report/Conference proceedingChapter

William Harbour, J & Mohsenin, A 2015, Second primary tumors in retinoblastoma. in Orbital Tumors: Diagnosis and Treatment, Second Edition. Springer New York, pp. 37-41. https://doi.org/10.1007/978-1-4939-1510-1_5
William Harbour J, Mohsenin A. Second primary tumors in retinoblastoma. In Orbital Tumors: Diagnosis and Treatment, Second Edition. Springer New York. 2015. p. 37-41 https://doi.org/10.1007/978-1-4939-1510-1_5
William Harbour, J. ; Mohsenin, Amir. / Second primary tumors in retinoblastoma. Orbital Tumors: Diagnosis and Treatment, Second Edition. Springer New York, 2015. pp. 37-41
@inbook{8a713df626b04e51ae44384afd23933a,
title = "Second primary tumors in retinoblastoma",
abstract = "Advances in the diagnosis and treatment of retinoblastoma have vastly improved patient outcomes. In developed countries, the most common cause of death in patients with heritable retinoblastoma is now a second primary tumor occurring in retinoblastoma survivors; many of these second primaries can be avoided by the reduced use of radiation. Mesenchymal tumors including primitive neuroectodermal tumors, bone and soft tissue sarcomas, leiomyomas, lipomas, cutaneous melanomas, and gliomas are the most common types of the second primary tumors in retinoblastoma survivors. Osteogenic sarcoma is the most common type of second primary tumor particularly in younger patients. Widespread use of systemic chemotherapy only started in the mid-1990s, so it is still too early to know its long-term risk of second primary tumors. Ophthalmic arterial chemotherapy has been widely used for only a few years and, while a major goal of this therapy is to reduce systemic exposure to chemotherapy, a significant amount of radiation exposure to the orbit is required for the fluoroscopy needed to cannulate the ophthalmic artery. Thus, it will be many years before we know the long-term risk of ocular tumors associated with ophthalmic arterial chemotherapy. Regardless of the therapy used to treat intraocular retinoblastoma, it is important to provide lifelong surveillance for second primary tumors that may arise in the orbit and elsewhere in patients with germline retinoblastoma.",
author = "{William Harbour}, J. and Amir Mohsenin",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-1510-1_5",
language = "English (US)",
isbn = "9781493915101",
pages = "37--41",
booktitle = "Orbital Tumors: Diagnosis and Treatment, Second Edition",
publisher = "Springer New York",

}

TY - CHAP

T1 - Second primary tumors in retinoblastoma

AU - William Harbour, J.

AU - Mohsenin, Amir

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Advances in the diagnosis and treatment of retinoblastoma have vastly improved patient outcomes. In developed countries, the most common cause of death in patients with heritable retinoblastoma is now a second primary tumor occurring in retinoblastoma survivors; many of these second primaries can be avoided by the reduced use of radiation. Mesenchymal tumors including primitive neuroectodermal tumors, bone and soft tissue sarcomas, leiomyomas, lipomas, cutaneous melanomas, and gliomas are the most common types of the second primary tumors in retinoblastoma survivors. Osteogenic sarcoma is the most common type of second primary tumor particularly in younger patients. Widespread use of systemic chemotherapy only started in the mid-1990s, so it is still too early to know its long-term risk of second primary tumors. Ophthalmic arterial chemotherapy has been widely used for only a few years and, while a major goal of this therapy is to reduce systemic exposure to chemotherapy, a significant amount of radiation exposure to the orbit is required for the fluoroscopy needed to cannulate the ophthalmic artery. Thus, it will be many years before we know the long-term risk of ocular tumors associated with ophthalmic arterial chemotherapy. Regardless of the therapy used to treat intraocular retinoblastoma, it is important to provide lifelong surveillance for second primary tumors that may arise in the orbit and elsewhere in patients with germline retinoblastoma.

AB - Advances in the diagnosis and treatment of retinoblastoma have vastly improved patient outcomes. In developed countries, the most common cause of death in patients with heritable retinoblastoma is now a second primary tumor occurring in retinoblastoma survivors; many of these second primaries can be avoided by the reduced use of radiation. Mesenchymal tumors including primitive neuroectodermal tumors, bone and soft tissue sarcomas, leiomyomas, lipomas, cutaneous melanomas, and gliomas are the most common types of the second primary tumors in retinoblastoma survivors. Osteogenic sarcoma is the most common type of second primary tumor particularly in younger patients. Widespread use of systemic chemotherapy only started in the mid-1990s, so it is still too early to know its long-term risk of second primary tumors. Ophthalmic arterial chemotherapy has been widely used for only a few years and, while a major goal of this therapy is to reduce systemic exposure to chemotherapy, a significant amount of radiation exposure to the orbit is required for the fluoroscopy needed to cannulate the ophthalmic artery. Thus, it will be many years before we know the long-term risk of ocular tumors associated with ophthalmic arterial chemotherapy. Regardless of the therapy used to treat intraocular retinoblastoma, it is important to provide lifelong surveillance for second primary tumors that may arise in the orbit and elsewhere in patients with germline retinoblastoma.

UR - http://www.scopus.com/inward/record.url?scp=84944061992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944061992&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1510-1_5

DO - 10.1007/978-1-4939-1510-1_5

M3 - Chapter

SN - 9781493915101

SN - 9781493915095

SP - 37

EP - 41

BT - Orbital Tumors: Diagnosis and Treatment, Second Edition

PB - Springer New York

ER -